Enfoque actual del tratamiento farmacológico del síndrome coronario agudo sin elevación del segmento st. de la fisiopatología al manejo

Vista sencilla de ítem
dc.contributor.advisorCano Rivera, Rodolfo
dc.contributor.advisorIglesias Acosta, Jesús
dc.contributor.authorAcosta Ariza, María Angélica
dc.contributor.authorRomo Escorcia, Fabio Camilo
dc.coverage.spatialBarranquillaspa
dc.creator.emailmaryacostaariza@hotmail.com, fcromoe2@hotmail.es
dc.date.accessioned2017-07-26T19:41:20Z
dc.date.available2017-07-26T19:41:20Z
dc.date.created2016
dc.description.abstractLos síndromes coronarios agudos son un problema mayor de salud pública en todo el mundo. El síndrome coronario agudo (SCA) incluye infarto agudo de miocardio (IAM), con o sin elevación del ST y la angina inestable. La incidencia anual de IAM sin elevación del segmento ST es 565.000 nuevos eventos y 300.000 ataques recurrentes cada año. Los factores de riesgo para presentar síndromes coronarios agudos incluyen: tabaquismo, niveles elevados de lípidos séricos, hipertensión arterial, diabetes mellitus, obesidad mórbida, sedentarismo, bajo consumo diario de frutas y vegetales, consumo problemático de alcohol e índice psicosocial. La evaluación inicial de un SCA SEST debe enfocarse en el dolor torácico, signos y síntomas asociados y factores de riesgo para SCA. Los marcadores biológicos de lesión miocárdica han evolucionado en la actualidad para una mejor precisión del abordaje diagnóstico y aportan datos para el pronóstico de los pacientes. El manejo actual de las nuevas drogas utilizadas mejora el pronóstico, disminuyen la mortalidad y mejoran la calidad de vida de los pacientes. Esta revisión bibliográfica se realizó con el propósito de actualizar los conocimientos sobre la fisiopatología el diagnóstico y el tratamiento del síndrome coronario agudo sin elevación del ST.spa
dc.formatPDF
dc.format.mimetypeapplication/pdf
dc.identifier.instnameinstname:Universidad Librespa
dc.identifier.reponamereponame:Repositorio Institucional Universidad Librespa
dc.identifier.urihttps://hdl.handle.net/10901/10239
dc.language.isospa
dc.relation.referencesRobert P. Giugliano, Christopher P. Cannon y Eugene Braunwald, Tratado De Cardiología, Texto De Medicina Cardiovascular, Síndromes Coronarios Agudos Sin Elevación Del ST, 10 ed. Volumen 1, El sevier. 2016; 53: 1155- 1181.SPA
dc.relation.referencesLozano R, Naghavi M, Foreman K. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010, The Lancet. 2012; 380:2095.eng
dc.relation.referencesAllan A. World Health Organization. Global status report on non-communicable diseases 2011. [Fecha de consulta: 25 de abril de 2016]. Disponible en: http://www.who.int/nmh/publications/ncd_report2010/es/.eng
dc.relation.referencesCubillos LA, Casas JP, Morillo C, Bautista LE. Congestive heart failure in Latin America: the next epidemic Am Heart J 2004; 147:412–7.eng
dc.relation.referencesMack M, Gopal A, Ambarish Gopal, Epidemiology, Traditional and Novel Risk Factors in Coronary Artery Disease, Cardiol Clin 32 (2014) 323–332eng
dc.relation.referencesAbegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet. 2007; 370:1929-38.eng
dc.relation.referencesStamler J, Stamler R, Neaton JD. Low riskfactor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA. 2012; 1999:282eng
dc.relation.referencesLloyd-Jones DM, Hong Y, Labarthe D. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s Strategic Impact Goal Through 2020 And Beyond. Circulation 2010; 121:586.eng
dc.relation.referencesSarwar N, Butterworth AS, Freitag DF. IL6R Genetics Consortium Emerging Risk Factors Collaboration, Interleukin-6 receptor pathway in coronary heart disease: a collaborative metaanalysis of 82 studies. Lancet 2012; 379:1205.eng
dc.relation.referencesKarakas M, Koenig W, Zierer A. Myeloperoxidase is associated with incident coronary heart disease independently of traditional risk factors: results from the MONICA/KORA Augsburg study. J Intern Med 2012; 271:43.eng
dc.relation.referencesKamin DS, Grinspoon SK. Cardiovascular disease in HIV-positive patients. AIDS 2005; 19:641.eng
dc.relation.referencesRoberts R, Steward AF. Genes and coronary artery disease: where are we? J Am Coll Cardiol 2012; 18:1715–21.eng
dc.relation.referencesohn M. Canty y Dirk J. Duncker, Tratado De Cardiología, Texto De Medicina Cardiovascular, Flujo Sanguíneo Coronario E Isquemia Miocardica, 10 ed. Volumen 1, El sevier, 2016; 49: 1029-1055.eng
dc.relation.referencesLiu Y, Gutterman DD: Vascular Control In Humans: Focus On The Coronary Microcirculation, Basic Res Cardiol. 2009; 104:211.eng
dc.relation.referencesBeyer AM, Gutterman DD: Regulation of the human coronary microcirculation, J Mol Cell Cardiol. 2012; 52:814eng
dc.relation.referencesZhang C, Rogers PA, Merkus D, et al: Regulation of coronary microvascular resistance in health and disease. In Tuma RF, Duran WN, Ley K, editors: Microcirculation, Boston, 2008, Elsevier, p 521.eng
dc.relation.referencesDeussen A, Ohanyan V, Jannasch A. Mechanisms of metabolic coronary flow regulation, J Mol Cell Cardiol. 2012; 52:794.eng
dc.relation.referencesAllam A, Thompson R. Atheroesclerosis In Ancient Egyptian Mummies, J am Coll Cardiol Img. 2011; 4 (4):315-327.eng
dc.relation.referencesChopra H.K, Nanda N. Cardiology: a clinical and historical perspective, the history of the acute coronary syndrome, 1ra edición. 2013; 12:87-90.eng
dc.relation.referencesPeter Libby, Tratado De Cardiología, Texto De Medicina Cardiovascular, biología vascular de la ateroesclerosis, 10 ed. Volumen 1, El sevier, 41:873-886, 2016.spa
dc.relation.referencesGimbrone MA, García-Cardena G. Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis, Cardiovasc Pathol. 2013: 22:9.eng
dc.relation.referencesPijls NH, Sels JW. Functional measurement of coronary stenosis, J Am Coll Cardiol. 2012; 59:1045.eng
dc.relation.referencesDe Bruyne B, Pijls NH, Kalesan B. Fractional flow reserve-guided pci versus medical therapy in stable coronary disease, N Engl J Med. 2012; 367:991.eng
dc.relation.referencesCamici PG, Olivotto I, Rimoldi OE. The coronary circulation and blood flow in left ventricular hypertrophy, J Mol Cell Cardiol. 2012; 52:857.eng
dc.relation.referencesHerrmann J, Kaski JC, Lerman A: Coronary microvascular dysfunction in the clinical setting: From mystery to reality, Eur Heart J. 2012; 33:2771.eng
dc.relation.referencesLanza GA, Crea F. Primary coronary microvascular dysfunction: Clinical presentation, pathophysiology, and management, Circulation. 2010; 121:2317.eng
dc.relation.referencesPeter Libby, Ira Tabas, Gabrielle Fredman, Edward A. Fisher, Inflammation and its Resolution as Determinants of Acute Coronary Syndromes, Circ Res. 2014;114:1867-1879.eng
dc.relation.referencesFog Bentzon J, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014; 114:1852–1866.eng
dc.relation.referencesLey K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol. 2011; 31:1506–1516.eng
dc.relation.referencesLibby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013; 368:2004–2013.eng
dc.relation.references.Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, et al, ESC guidelines for the management of acute myocardial infarction in patients presenting with STsegment elevation. Eur Heart J. 2012;33:2569–619eng
dc.relation.referencesThygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al, Third universal definition of myocardial infarction. Eur Heart J. 2012; 33:2551– 67.eng
dc.relation.referencesAnderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/NonSTElevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123(18):e426–579.eng
dc.relation.referencesBraunwald E, Morrow DA. Unstable angina: is it time for a requiem? Circulation. 2013;127:2452–7.eng
dc.relation.referencesAnderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non- 92 STElevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011 May 10;123(18):e426–579eng
dc.relation.referencesMorrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, et al, Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001; 286:2405–12.eng
dc.relation.referencesReichlin T, Twerenbold R, Reiter M, Steuer S, Bassetti S, Balmelli C, et al. Introduction of high-sensitivity troponin assays: impact on myocardial infarction incidence and prognosis. Am J Med. 2012; 125:1205–13, e1201eng
dc.relation.referencesIoannidis JP, Salem D, Chew PW, Lau J. Accuracy of imaging technologies in the diagnosis of acute cardiac ischemia in the emergency department: a metaanalysis. Ann Emerg Med. 2001; 37(5):471–7eng
dc.relation.referencesKontos MC, Kurdziel K, McQueen R, Arrowood JA, Jesse RL, Ornato JP, et al. Comparison of 2-dimensional echocardiography and myocardial perfusion imaging for diagnosing myocardial infarction in emergency department patients. Am. Heart J. 2002;143(4):659–67eng
dc.relation.referencesDe Araujo P, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur. Heart J. 2005; 26(9):865–72.eng
dc.relation.referencesKozieradzka A, Kamiński KA, Maciorkowska D, Olszewska M, Dobrzycki S, Nowak K, et al. GRACE, TIMI, Zwolle and CADILLAC risk scores — Do they predict 5-year outcomes after ST-elevation myocardial infarction treated invasively? International Journal of Cardiology. 2011; 148:70–5eng
dc.relation.referencesAbu-Assi E, Raposeiras-Roubin S, Lear P, Cabanas-Grandio P, Girondo M, Rodríguez-Cordero M, et al. Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome. Eur Heart J Acute Cardiovasc Care. 2012;1:222–31.eng
dc.relation.referencesAkkerhuis KM, Klootwijk PA, Lindeboom W, Umans VA, Meij S, Kint PP, Simoons ML. Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients. Eur Heart J. 2001; 22:1997–2006eng
dc.relation.referencesSchwartz BG, Kloner RA. Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. Circulation. 2010;122:88–95eng
dc.relation.referencesChatterjee S, Chaudhuri D, Vedanthan R, Fuster V, Ibanez B, Bangalore S, Mukherjee D. Early intravenous beta-blockers in patients with acute coronary syndrome—a meta-analysis of randomized trials. Int J Cardiol. 2013; 168:915– 21. 120eng
dc.relation.referencesKontos MC, Diercks DB, Ho PM, Wang TY, Chen AY, Roe MT. Treatment and outcomes in patients with myocardial infarction treated with acute beta-blocker therapy: results from the American College of Cardiology’s NCDRw. Am Heart J. 2011; 161:864–70.eng
dc.relation.referencesBerger JS, Stebbins A, Granger CB, Ohman EM, Armstrong PW, Van de Werf F, et al. Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation. 2008;117(2):192-9eng
dc.relation.referencesBauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ. 2011; 343:d4588.eng
dc.relation.referencesGurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009.eng
dc.relation.referencesWallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045- 57. 100. Mahaffey KW, Weng
dc.relation.referencesCannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised doubleblind study. Lancet. 2010;375(9711):283-93eng
dc.relation.referencesHarrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ. et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133eng
dc.relation.referencesBhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2008;103(11):2890-907eng
dc.relation.referencesFox KA, Bassand JP, Mehta SR, Wallentin L, Theroux P, Piegas LS, et al. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med. 2007; 147(5):304-10. 144eng
dc.relation.referencesStone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006; 355(21):2203-16.eng
dc.relation.references.Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA. 2007; 298(21):2497-506. 155.eng
dc.relation.referencesHansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrom SZ, Poulsen HE, Kober L, Torp-Pedersen C. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170:1433–4eng
dc.relation.referencesEerenberg ES, KamphuisenPW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011; 124:1573–9.eng
dc.relation.referencesPfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Jr., Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992; 327(10): 669- 77.eng
dc.relation.referencesLubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/ metoprolol Trial (HINT). Am J Cardiol. 1987; 60(2):18A-25A.eng
dc.relation.referencesWood D, De Backer G, Faergemann O, Graham I, Mancia G, Mancia G on behalf of the Task Force Prevention of coronary heart disease in clinical practice. Recommendation of the Second Joint task Force of European and Societies on coronary prevention. Eur Heart J. 1998; 19: 1434-503.eng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.licenseAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.subjectSíndrome coronario agudospa
dc.subjectSalud públicaspa
dc.subjectInfarto agudo de miocardiospa
dc.subject.lembENFERMEDAD CORONARIAspa
dc.subject.proposalSíndromes coronarios agudosspa
dc.subject.proposalEpidemiologíaspa
dc.subject.proposalDiagnósticospa
dc.titleEnfoque actual del tratamiento farmacológico del síndrome coronario agudo sin elevación del segmento st. de la fisiopatología al manejospa
dc.type.coarhttp://purl.org/coar/resource_type/c_7a1fspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.driverinfo:eu-repo/semantics/bachelorThesisspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localTesis de Especializaciónspa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
TESIS FINAL DE INFARTO 2016-I.pdf
Tamaño:
1.27 MB
Formato:
Adobe Portable Document Format
Descripción:
Trabajo de Grado
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Especialización en Medicina Interna